Skip to main content
SpringerLink
Log in
Book cover

Wnt Signaling pp 67–75Cite as

Inhibition of Glycogen Synthase Kinase-3

  • Protocol

Part of the book series: Methods in Molecular Biology™ ((MIMB,volume 468))

Abstract

There are two homologous forms of glycogen synthase kinase (GSK)-3, GSK-3α and GSK-3β, which play overlapping roles in the regulation of Wnt, Hedgehog, and insulin pathways, as well as the activation of nuclear factor (NF)-kB-mediated gene transcription. These signaling pathways regulate gene transcription, cell cycle, apoptosis, inflammation, glucose metabolism, stem-cell renewal, and differentiation. More than 50 GSK-3 inhibitors representing a wide range of chemical structures have already been identified, and their utility in the treatment of type II diabetes mellitus, Alzheimer's disease, bipolar diseases, cancer, and other human pathologies is currently being investigated. Here, we discuss two methods of GSK-3 inhibition, which can be used to determine the involvement of GSK-3 in a cellular process of interest.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Plyte SE, Hughes K, Nikolakaki E, Pulverer BJ, Wood-gett JR. (1992) Glycogen synthase kinase-3: functions in oncogenesis and development. Biochim Biophys Acta. 1114, 147–162.

    CAS  PubMed  Google Scholar 

  2. Frame S, Cohen P. (2001) GSK3 takes centre stage more than 20 years after its discovery. Biochem J. 359, 1–16.

    Article  CAS  PubMed  Google Scholar 

  3. Doble BW, Woodgett JR. (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci. 116, 1175–1186.

    Article  CAS  PubMed  Google Scholar 

  4. Cohen P, Frame S. (2001) The renaissance of GSK3. Nat Rev Mol Cell Biol. 2, 769–776.

    Article  CAS  PubMed  Google Scholar 

  5. Cohen P, Goedert M. (2004) GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov. 3, 479–487.

    Article  CAS  PubMed  Google Scholar 

  6. Ougolkov AV, Billadeau DD. (2006) Targeting GSK-3: a promising approach for cancer therapy? Future Oncol. 2, 91–100.

    Article  CAS  PubMed  Google Scholar 

  7. Dugo L, Collin M, Thiemermann C. (2007) Glycogen synthase kinase 3beta as a target for the therapy of shock and inflammation. Shock. 27, 113–123.

    Article  CAS  PubMed  Google Scholar 

  8. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P. (1996) Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science. 272, 1023–1026.

    Article  CAS  PubMed  Google Scholar 

  9. Yamamoto H, Kishida S, Kishida M, Ikeda S, Takada S, Kikuchi A. (1999) Phosphorylation of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3beta regulates its stability. J Biol Chem. 274, 10681–10684.

    Article  CAS  PubMed  Google Scholar 

  10. Ding VW, Chen RH, McCormick F. (2000) Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling. J Biol Chem. 275, 32475–32481.

    Article  CAS  PubMed  Google Scholar 

  11. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. (2000) Requirement for gly-cogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature. 406, 86–90.

    Article  CAS  PubMed  Google Scholar 

  12. Meijer L, Flajolet M, Greengard P. (2004) Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci. 25, 471–480.

    Article  CAS  PubMed  Google Scholar 

  13. Martinez A, Castro A, Dorronsoro I, Alonso M. (2002) Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev. 22, 373–384.

    Article  CAS  PubMed  Google Scholar 

  14. Alonso M, Martinez A. (2004) GSK-3 inhibitors: discoveries and developments. Curr Med Chem. 11, 755–763.

    Article  CAS  PubMed  Google Scholar 

  15. Stambolic V, Ruel L, Woodgett JR. (1996) Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol. 6, 1664–1668.

    Article  CAS  PubMed  Google Scholar 

  16. Ryves WJ, Harwood AJ. (2001) Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun. 280, 720–725.

    Article  CAS  PubMed  Google Scholar 

  17. Mora A, Sabio G, Gonzalez-Polo RA, et al. (2001) Lithium inhibits caspase 3 activation and dephosphorylation of PKB and GSK3 induced by K+ deprivation in cerebellar granule cells. J Neurochem. 78, 199–206.

    Article  CAS  PubMed  Google Scholar 

  18. Ilouz R, Kaidanovich O, Gurwitz D, Eldar-Finkelman H. (2002) Inhibition of glycogen synthase kinase-3beta by bivalent zinc ions: insight into the insulin-mimetic action of zinc. Biochem Biophys Res Commun. 295, 102–106.

    Article  CAS  PubMed  Google Scholar 

  19. Leclerc S, Garnier M, Hoessel R, et al. (2001) Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphor ylation in Alzheimer's disease. A p r operty common to most cyclin-dependent kinase inhibitors? J Biol Chem. 276, 251–260.

    Article  CAS  PubMed  Google Scholar 

  20. Leost M, Schultz C, Link A, et al. (2000) Paullones are potent inhibitors of glycogen syn-thase kinase-3beta and cyclin-dependent kinase 5/p25. Eur J Biochem. 267, 5983–5994.

    Article  CAS  PubMed  Google Scholar 

  21. Smith DG, Buffet M, Fenwick AE, et al. (2001) 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg Med Chem Lett. 11, 635–639.

    Article  CAS  PubMed  Google Scholar 

  22. Cross DA, Culbert AA, Chalmers KA, Facci L, Skaper SD, Reith AD. (2001) Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J Neurochem. 77, 94–102.

    Article  CAS  PubMed  Google Scholar 

  23. Bhat R, Xue Y, Berg S, et al. (2003) Structural insights and biological effects of glycogen syn-thase kinase 3-specific inhibitor AR-A014418. J Biol Chem. 278, 45937–45945.

    Article  CAS  PubMed  Google Scholar 

  24. Martinez A, Alonso M, Castro A, Perez C, Moreno FJ. (2002) First non-ATP competitive glycogen synthase kinase 3 beta (GSK-beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem. 45, 1292–1299.

    Article  CAS  PubMed  Google Scholar 

  25. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD. (2005) Glycogen synthase kinase-3beta participates in nuclear factor kappaB-medi-ated gene transcription and cell survival in pancreatic cancer cells. Cancer Res. 65, 2076–2081.

    Article  CAS  PubMed  Google Scholar 

  26. Zakaria S, Gomez TS, Savoy DN, et al. (2004) Differential regulation of TCR-mediated gene transcription by Vav family members. J Exp Med. 199, 429–434.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported in part by the Mayo Foundation, and a Specialized Program of Research Excellence (SPORE) grant in pancreatic cancer (P50 CA102701) to DDB.

Author information

Authors and Affiliations

  1. Division of Oncology Research, Mayo Clinic College of Medicine, Rochester MN, USA

    Andrei V. Ougolkov & Daniel D. Billadeau

Authors
  1. Andrei V. Ougolkov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel D. Billadeau
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Melbourne, Parkville, Victoria, VIC 3010, Australia

    Elizabeth Vincan PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Ougolkov, A.V., Billadeau, D.D. (2008). Inhibition of Glycogen Synthase Kinase-3. In: Vincan, E. (eds) Wnt Signaling. Methods in Molecular Biology™, vol 468. Humana Press. https://doi.org/10.1007/978-1-59745-249-6_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-249-6_5

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-912-3

  • Online ISBN: 978-1-59745-249-6

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation